Involved Site Radiotherapy Extends Time to Premature Menopause in Infra-Diaphragmatic Female Hodgkin Lymphoma Patients - An Analysis of GHSG HD14- and HD17-Patients.
Hodgkin lymphoma
chemotherapy
fertility
infradiaphragmatic
involved field radiotherapy
involved site radiotherapy
premature menopause
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
25
01
2021
accepted:
06
05
2021
entrez:
11
6
2021
pubmed:
12
6
2021
medline:
12
6
2021
Statut:
epublish
Résumé
Consolidation radiotherapy in intermediate stage Hodgkin´s lymphoma (HL) has been the standard of care for many years as involved field radiotherapy (IFRT) after chemotherapy. It included initially involved region(s). Based on randomized studies, radiation volumes could be reduced and involved site radiation therapy (ISRT) became the new standard. ISRT includes the initially affected lymph nodes. In young adults suffering from HL, infertility and hypogonadism are major concerns. With regard to these questions, we analyzed the influence of modern radiotherapy concepts such as consolidating ISRT in infradiaphragmatic involvement of HL after polychemotherapy. Five hundred twelve patients treated within German Hodgkin Study Group (GHSG) HD14 and HD17 trials were evaluated. We analyzed log-adjusted follicle-stimulating-hormone (FSH)- and luteinizing-hormone (LH)-levels of HD14-patients with infradiaphragmatic radiotherapy (IDRT) in comparison with HD14-patients, who had a supradiaphragmatic radiotherapy (SDRT). In a second step, we compared IFRT with ISRT of female HD17 patients regarding the effects on ovarian function and premature menopause. We analyzed FSH- and LH-levels of 258 female and 241 male patients, all treated with IFRT. Of these 499 patients, 478 patients had SDRT and 21 patients had IDRT. In a multiple regression model, we could show that log-adjusted FSH (p=0.0006) and LH values (p=0.0127) were significantly higher after IDRT than after SDRT. The effect of IDRT on gonadal function was comparable to two cycles of escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc). We compared the effect of IFRT with ISRT in thirteen female HD17 patients with infradiaphragmatic (ID) involvement. The mean ovarian dose after ISRT was significantly lower than after IFRT. The calculated proportion of surviving non-growing follicles (NGFs) increased significantly from 11.87% to 24.48% in ISRT compared to IFRT, resulting in a significantly longer calculated time to menopause. The younger the age at therapy, the greater the absolute time gain until menopause. Infradiaphragmatic IFRT impairs gonadal function to a similar extent as two cycles of BEACOPPesc. In comparison, the use of ISRT target volume definition significantly reduced radiation dose to the ovaries and significantly extends the time interval from treatment to premature menopause.
Identifiants
pubmed: 34113567
doi: 10.3389/fonc.2021.658358
pmc: PMC8185193
doi:
Types de publication
Journal Article
Langues
eng
Pagination
658358Informations de copyright
Copyright © 2021 Rosenbrock, Vásquez-Torres, Mueller, Behringer, Zerth, Celik, Fan, Trommer, Linde, Fuchs, Borchmann, Engert, Marnitz and Baues.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Pediatr Blood Cancer. 2018 Sep;65(9):e27232
pubmed: 29750388
Cancer. 1976 Dec;38(6):2263-8
pubmed: 826312
Ann Hematol. 2019 Aug;98(8):1947-1952
pubmed: 30997537
J Clin Oncol. 2017 Jun 1;35(16):1786-1794
pubmed: 28291393
Clin Oncol (R Coll Radiol). 1989 Nov;1(2):75-9
pubmed: 2486484
J Clin Oncol. 2003 Oct 1;21(19):3601-8
pubmed: 12913100
Maturitas. 2003 Apr 25;44(4):279-86
pubmed: 12697368
J Natl Cancer Inst. 2006 Oct 18;98(20):1453-61
pubmed: 17047194
Biomed Res Int. 2014;2014:482968
pubmed: 25165706
J Clin Oncol. 1987 Nov;5(11):1759-65
pubmed: 3119785
Ann Oncol. 2012 Jul;23(7):1818-25
pubmed: 22228451
Lancet. 2012 May 12;379(9828):1791-9
pubmed: 22480758
Cancer. 1996 Jun 15;77(12):2638-45
pubmed: 8640716
Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1481-6
pubmed: 19147304
Menopause. 2007 May-Jun;14(3 Pt 2):567-71
pubmed: 17476146
Clin Oncol (R Coll Radiol). 2015 Jul;27(7):401-10
pubmed: 25840609
Lancet. 2018 Dec 23;390(10114):2790-2802
pubmed: 29061295
Hum Reprod. 2008 Mar;23(3):699-708
pubmed: 18192670
Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):854-62
pubmed: 23790512
Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):738-44
pubmed: 15936554
J Natl Cancer Inst. 2014 Aug 19;106(9):
pubmed: 25139687
Int J Gynecol Cancer. 2010 Aug;20(6):1082-6
pubmed: 20683422
Radiology. 1989 Jan;170(1 Pt 1):55-8
pubmed: 2909120
J Clin Oncol. 2012 Mar 20;30(9):907-13
pubmed: 22271480
J Clin Oncol. 2013 Jan 10;31(2):231-9
pubmed: 23150709
Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1057-65
pubmed: 23200817
Br J Cancer. 1976 Feb;33(2):226-31
pubmed: 1259916
Oncology. 2016;91(5):295-298
pubmed: 27677176
Lancet. 2015 Apr 11;385(9976):1418-27
pubmed: 25539730
Menopause. 2007 May-Jun;14(3 Pt 2):562-6
pubmed: 17476145
Phys Med. 2019 Jan;57:100-106
pubmed: 30738513
J Clin Oncol. 2019 Nov 1;37(31):2835-2845
pubmed: 31498753
Bone Marrow Transplant. 1998 Feb;21(3):287-90
pubmed: 9489652
J Clin Oncol. 1990 Dec;8(12):1981-7
pubmed: 2121911
J Psychosom Obstet Gynaecol. 2000 Sep;21(3):167-74
pubmed: 11076338
Ann Oncol. 2006 Sep;17(9):1428-33
pubmed: 16831852
Acta Obstet Gynecol Scand. 2004 Jan;83(1):96-102
pubmed: 14678092
Eur J Prev Cardiol. 2016 Jan;23(2):178-86
pubmed: 25331207
Hum Reprod. 2003 Jan;18(1):117-21
pubmed: 12525451
Med Phys. 2017 Jul;44(7):3866-3874
pubmed: 28493609
J Clin Oncol. 2012 Jan 20;30(3):291-9
pubmed: 22184372
Radiother Oncol. 2003 Sep;68(3):249-53
pubmed: 13129632
Blood. 2008 Jan 1;111(1):101-8
pubmed: 17890454